Limited T cell response to SARS-CoV-2 mRNA vaccine among patients with cancer receiving different cancer treatments

Patients with cancer (PC) are at high risk of acquiring COVID-19 and can develop more serious complications. Deeper understanding of vaccines immunogenicity in this population is crucial for adequately planning vaccines programs. The ONCOVac study aimed to comprehensively assess the immunogenicity o...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of cancer (1990) 2022-05, Vol.166, p.229-239
Hauptverfasser:	Cortés, Alfonso, Casado, José L., Longo, Federico, Serrano, Juan J., Saavedra, Cristina, Velasco, Héctor, Martin, Adrián, Chamorro, Jesús, Rosero, Diana, Fernández, María, Gion, María, Martínez Jáñez, Noelia, Soria Rivas, Ainara, Alonso Gordoa, Teresa, Martínez Delfrade, Íñigo, Lage, Yolanda, López Miranda, Elena, Olmedo, María E., Reguera Puertas, Pablo, Gajate, Pablo, Molina Cerrillo, Javier, Guerra Alia, Eva, Fuentes Mateos, Raquel, Romero, Beatriz, Rodríguez-Domínguez, Mario J., Vallejo, Alejandro, Carrato, Alfredo
Format:	Artikel
Sprache:	eng
Schlagworte:	2019-nCoV Vaccine mRNA-1273 Antibodies, Viral Cancer Cancer therapies Cancer vaccines CD4 antigen CD8 antigen Cellular response Chemotherapy Complications Coronaviruses COVID-19 COVID-19 - prevention & control COVID-19 vaccines COVID-19 Vaccines - adverse effects Cyclin-dependent kinases Dosage Health care Humans Humoral response Immune response (humoral) Immunization Immunogenicity Immunoglobulin G Immunotherapy Kinases Lymphocytes Lymphocytes T Medical personnel mRNA mRNA Vaccines Neoplasms - therapy Original Research Patients Prospective Studies Safety SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 Solid tumors Solid tumours Tumors Vaccination Vaccines Vaccines, Synthetic
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!